| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Drug Hypersensitivity | 14 | 2019 | 401 | 4.90 | Why? |
| HLA Antigens | 7 | 2018 | 830 | 2.02 | Why? |
| Anaphylaxis | 9 | 2021 | 940 | 1.98 | Why? |
| HLA-B Antigens | 6 | 2018 | 166 | 1.47 | Why? |
| Skin Tests | 7 | 2021 | 229 | 1.43 | Why? |
| Drug Hypersensitivity Syndrome | 2 | 2019 | 74 | 1.30 | Why? |
| HLA-A Antigens | 5 | 2019 | 196 | 1.29 | Why? |
| Penicillins | 7 | 2019 | 132 | 1.29 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 5 | 2018 | 1261 | 1.18 | Why? |
| Allergens | 5 | 2018 | 728 | 1.17 | Why? |
| Anti-Bacterial Agents | 11 | 2019 | 10083 | 1.11 | Why? |
| T-Lymphocytes | 11 | 2018 | 6670 | 1.06 | Why? |
| Hypersensitivity, Delayed | 3 | 2018 | 81 | 0.85 | Why? |
| Alleles | 8 | 2019 | 1557 | 0.80 | Why? |
| Product Surveillance, Postmarketing | 1 | 2021 | 189 | 0.76 | Why? |
| HLA-DP Antigens | 4 | 2019 | 38 | 0.74 | Why? |
| Polysorbates | 1 | 2018 | 125 | 0.74 | Why? |
| Anti-HIV Agents | 5 | 2017 | 2209 | 0.74 | Why? |
| Carbamazepine | 1 | 2018 | 34 | 0.73 | Why? |
| HLA-DQ Antigens | 4 | 2018 | 48 | 0.71 | Why? |
| Histocompatibility Antigens Class II | 2 | 2017 | 383 | 0.69 | Why? |
| Hypersensitivity, Immediate | 1 | 2018 | 134 | 0.66 | Why? |
| beta-Lactams | 1 | 2019 | 210 | 0.66 | Why? |
| Raltegravir Potassium | 1 | 2017 | 132 | 0.64 | Why? |
| HLA-C Antigens | 4 | 2018 | 195 | 0.63 | Why? |
| Cobicistat | 1 | 2017 | 172 | 0.62 | Why? |
| Drug Eruptions | 2 | 2018 | 319 | 0.62 | Why? |
| Vancomycin | 1 | 2019 | 328 | 0.60 | Why? |
| Pneumococcal Vaccines | 1 | 2021 | 571 | 0.59 | Why? |
| HLA-DR Antigens | 4 | 2018 | 563 | 0.59 | Why? |
| Receptors, Antigen, T-Cell | 2 | 2019 | 760 | 0.59 | Why? |
| Polyethylene Glycols | 2 | 2021 | 574 | 0.57 | Why? |
| Cross Reactions | 5 | 2020 | 4374 | 0.50 | Why? |
| Genetic Predisposition to Disease | 6 | 2018 | 4027 | 0.49 | Why? |
| Histocompatibility Antigens Class I | 1 | 2017 | 624 | 0.48 | Why? |
| Stevens-Johnson Syndrome | 3 | 2018 | 129 | 0.45 | Why? |
| HIV | 1 | 2018 | 1116 | 0.44 | Why? |
| Peptides | 3 | 2018 | 2513 | 0.44 | Why? |
| Vaccines, Synthetic | 2 | 2020 | 3231 | 0.44 | Why? |
| Dengue Virus | 4 | 2019 | 910 | 0.42 | Why? |
| Sulfonamides | 2 | 2019 | 1294 | 0.42 | Why? |
| HIV Infections | 6 | 2018 | 11620 | 0.42 | Why? |
| Anti-Retroviral Agents | 1 | 2018 | 1099 | 0.40 | Why? |
| Antimicrobial Stewardship | 2 | 2018 | 931 | 0.40 | Why? |
| Interdisciplinary Communication | 1 | 2017 | 1425 | 0.39 | Why? |
| Interferon-gamma | 3 | 2019 | 2711 | 0.38 | Why? |
| Lymphocyte Activation | 2 | 2018 | 2742 | 0.37 | Why? |
| Pharmacogenetics | 2 | 2018 | 222 | 0.32 | Why? |
| Immunoglobulin E | 3 | 2018 | 557 | 0.31 | Why? |
| Epitopes, T-Lymphocyte | 6 | 2020 | 2262 | 0.31 | Why? |
| Gene Frequency | 7 | 2018 | 1210 | 0.30 | Why? |
| Immunocompromised Host | 2 | 2019 | 5150 | 0.30 | Why? |
| Histocompatibility Testing | 4 | 2018 | 219 | 0.28 | Why? |
| Skin | 1 | 2017 | 2096 | 0.28 | Why? |
| Immunologic Memory | 5 | 2020 | 3362 | 0.27 | Why? |
| CD4-Positive T-Lymphocytes | 4 | 2020 | 4545 | 0.26 | Why? |
| Peptococcaceae | 2 | 2019 | 2 | 0.24 | Why? |
| Dengue | 4 | 2019 | 1565 | 0.24 | Why? |
| Viral Vaccines | 2 | 2021 | 7560 | 0.24 | Why? |
| Drug Repositioning | 1 | 2021 | 5683 | 0.24 | Why? |
| Ritonavir | 2 | 2017 | 4212 | 0.24 | Why? |
| Genetics, Population | 2 | 2017 | 162 | 0.20 | Why? |
| Humans | 61 | 2021 | 930598 | 0.20 | Why? |
| Chloroform | 1 | 2019 | 11 | 0.20 | Why? |
| Virus Diseases | 1 | 2017 | 3779 | 0.20 | Why? |
| Enzyme-Linked Immunospot Assay | 2 | 2017 | 325 | 0.20 | Why? |
| Methylene Chloride | 1 | 2018 | 2 | 0.19 | Why? |
| Lamin Type A | 1 | 2018 | 14 | 0.19 | Why? |
| Protein Tyrosine Phosphatases | 1 | 2018 | 12 | 0.19 | Why? |
| Groundwater | 1 | 2019 | 45 | 0.19 | Why? |
| Mitogen-Activated Protein Kinase 3 | 1 | 2018 | 44 | 0.19 | Why? |
| Genotype | 7 | 2018 | 4697 | 0.18 | Why? |
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2019 | 170 | 0.18 | Why? |
| Epitope Mapping | 3 | 2020 | 1240 | 0.18 | Why? |
| Dideoxynucleosides | 1 | 2018 | 92 | 0.18 | Why? |
| Drug Labeling | 1 | 2018 | 65 | 0.18 | Why? |
| Drug Tolerance | 1 | 2018 | 100 | 0.18 | Why? |
| Succinate Dehydrogenase | 1 | 2017 | 16 | 0.18 | Why? |
| Allopurinol | 1 | 2018 | 59 | 0.18 | Why? |
| Nevirapine | 1 | 2017 | 57 | 0.17 | Why? |
| Duodenal Neoplasms | 1 | 2017 | 24 | 0.17 | Why? |
| Gout Suppressants | 1 | 2018 | 54 | 0.17 | Why? |
| Drug Resistance, Microbial | 2 | 2018 | 419 | 0.17 | Why? |
| alpha-Synuclein | 1 | 2017 | 71 | 0.17 | Why? |
| Immunocompetence | 1 | 2018 | 280 | 0.16 | Why? |
| Lymphoma, Follicular | 1 | 2017 | 109 | 0.16 | Why? |
| Gastrointestinal Stromal Tumors | 1 | 2017 | 84 | 0.16 | Why? |
| Tetanus Toxoid | 1 | 2017 | 136 | 0.15 | Why? |
| Quinolones | 1 | 2017 | 167 | 0.15 | Why? |
| beta-Lactamases | 2 | 2018 | 759 | 0.15 | Why? |
| Stem Cell Transplantation | 1 | 2020 | 531 | 0.14 | Why? |
| Serogroup | 1 | 2017 | 510 | 0.14 | Why? |
| Atazanavir Sulfate | 1 | 2017 | 213 | 0.14 | Why? |
| RNA, Messenger | 4 | 2021 | 5131 | 0.14 | Why? |
| Autoantigens | 1 | 2017 | 388 | 0.14 | Why? |
| Risk | 2 | 2017 | 5288 | 0.14 | Why? |
| Tobacco Smoke Pollution | 1 | 2017 | 181 | 0.14 | Why? |
| Chemoprevention | 1 | 2019 | 585 | 0.14 | Why? |
| Genetic Testing | 1 | 2017 | 395 | 0.13 | Why? |
| Inappropriate Prescribing | 1 | 2017 | 284 | 0.13 | Why? |
| AIDS Vaccines | 1 | 2018 | 452 | 0.13 | Why? |
| Darunavir | 1 | 2017 | 477 | 0.13 | Why? |
| Polymorphism, Genetic | 2 | 2017 | 1074 | 0.13 | Why? |
| Linkage Disequilibrium | 3 | 2018 | 191 | 0.13 | Why? |
| Haplotypes | 1 | 2017 | 853 | 0.13 | Why? |
| Th2 Cells | 1 | 2017 | 680 | 0.12 | Why? |
| Anticonvulsants | 1 | 2018 | 634 | 0.12 | Why? |
| Cytomegalovirus | 1 | 2017 | 600 | 0.12 | Why? |
| Sequence Analysis, DNA | 5 | 2018 | 2830 | 0.12 | Why? |
| Antigens, Viral | 3 | 2017 | 6298 | 0.11 | Why? |
| Mice | 4 | 2018 | 21357 | 0.11 | Why? |
| Male | 23 | 2021 | 367725 | 0.11 | Why? |
| Immunomodulation | 1 | 2020 | 1472 | 0.11 | Why? |
| T-Lymphocyte Subsets | 1 | 2019 | 1387 | 0.11 | Why? |
| Multiple Myeloma | 1 | 2020 | 1064 | 0.11 | Why? |
| Cytomegalovirus Infections | 1 | 2017 | 667 | 0.11 | Why? |
| Mice, Transgenic | 1 | 2018 | 2739 | 0.11 | Why? |
| CD8-Positive T-Lymphocytes | 2 | 2019 | 5837 | 0.11 | Why? |
| Rhinitis, Allergic | 1 | 2018 | 704 | 0.11 | Why? |
| Female | 22 | 2021 | 380317 | 0.11 | Why? |
| Th1 Cells | 1 | 2017 | 1228 | 0.10 | Why? |
| Hypersensitivity | 1 | 2021 | 1137 | 0.10 | Why? |
| Animals | 7 | 2018 | 78931 | 0.10 | Why? |
| Protein Binding | 2 | 2017 | 11430 | 0.10 | Why? |
| Middle Aged | 17 | 2021 | 270681 | 0.10 | Why? |
| Cancer Survivors | 1 | 2017 | 588 | 0.10 | Why? |
| Drug Interactions | 1 | 2017 | 1653 | 0.10 | Why? |
| Hospitals | 2 | 2021 | 11793 | 0.10 | Why? |
| Drug Prescriptions | 1 | 2018 | 1062 | 0.10 | Why? |
| Rituximab | 1 | 2017 | 1096 | 0.10 | Why? |
| Biodegradation, Environmental | 2 | 2019 | 52 | 0.10 | Why? |
| Carbon Isotopes | 2 | 2019 | 141 | 0.09 | Why? |
| Cardiomyopathies | 1 | 2018 | 997 | 0.09 | Why? |
| Mycobacterium tuberculosis | 1 | 2018 | 1164 | 0.09 | Why? |
| Precision Medicine | 1 | 2018 | 1477 | 0.09 | Why? |
| Microbial Sensitivity Tests | 1 | 2017 | 2886 | 0.09 | Why? |
| Aged | 11 | 2021 | 215776 | 0.09 | Why? |
| Leukocytes, Mononuclear | 1 | 2017 | 2115 | 0.09 | Why? |
| Self Report | 1 | 2019 | 3802 | 0.08 | Why? |
| Polymorphism, Single Nucleotide | 2 | 2017 | 3607 | 0.08 | Why? |
| Phenotype | 1 | 2018 | 4037 | 0.08 | Why? |
| Protein Conformation | 1 | 2017 | 4386 | 0.08 | Why? |
| Adult | 16 | 2021 | 244371 | 0.07 | Why? |
| Pilot Projects | 1 | 2017 | 5182 | 0.07 | Why? |
| Transcriptome | 1 | 2019 | 3466 | 0.07 | Why? |
| Odds Ratio | 1 | 2017 | 5861 | 0.07 | Why? |
| Parkinson Disease | 1 | 2017 | 1414 | 0.07 | Why? |
| Zika Virus | 1 | 2017 | 1924 | 0.07 | Why? |
| Disease Susceptibility | 1 | 2017 | 4002 | 0.07 | Why? |
| Australia | 1 | 2017 | 6306 | 0.07 | Why? |
| Risk Assessment | 2 | 2018 | 25439 | 0.06 | Why? |
| Molecular Docking Simulation | 1 | 2019 | 6902 | 0.06 | Why? |
| Models, Molecular | 1 | 2017 | 7616 | 0.06 | Why? |
| HIV-1 | 1 | 2017 | 3365 | 0.06 | Why? |
| History, 21st Century | 2 | 2017 | 1849 | 0.06 | Why? |
| Interleukin-6 | 1 | 2020 | 7522 | 0.06 | Why? |
| Tuberculosis | 1 | 2018 | 2895 | 0.06 | Why? |
| Databases, Genetic | 2 | 2018 | 1127 | 0.06 | Why? |
| Antineoplastic Agents | 1 | 2017 | 3550 | 0.06 | Why? |
| Vaccination | 3 | 2021 | 19050 | 0.06 | Why? |
| Adolescent | 5 | 2019 | 86841 | 0.05 | Why? |
| Risk Factors | 3 | 2018 | 71621 | 0.05 | Why? |
| Young Adult | 4 | 2019 | 93724 | 0.05 | Why? |
| Receptors, CCR7 | 1 | 2019 | 40 | 0.05 | Why? |
| HIV Protease Inhibitors | 1 | 2003 | 434 | 0.05 | Why? |
| Genome-Wide Association Study | 2 | 2017 | 1648 | 0.05 | Why? |
| Halogenation | 1 | 2019 | 51 | 0.05 | Why? |
| Leukocyte Common Antigens | 1 | 2019 | 101 | 0.05 | Why? |
| Asthma | 1 | 2018 | 4383 | 0.05 | Why? |
| Re-Epithelialization | 1 | 2018 | 29 | 0.05 | Why? |
| Minimal Clinically Important Difference | 1 | 2018 | 39 | 0.05 | Why? |
| Sequence Homology | 1 | 2020 | 448 | 0.05 | Why? |
| Cyclophosphamide | 1 | 2020 | 387 | 0.05 | Why? |
| Chlorine | 1 | 2018 | 55 | 0.05 | Why? |
| Viral Proteins | 1 | 2017 | 7370 | 0.05 | Why? |
| HLA-DR7 Antigen | 1 | 2017 | 6 | 0.05 | Why? |
| Cohort Studies | 2 | 2021 | 36005 | 0.05 | Why? |
| Anaerobiosis | 1 | 2018 | 146 | 0.05 | Why? |
| Case-Control Studies | 1 | 2017 | 17671 | 0.04 | Why? |
| Nicaragua | 1 | 2017 | 71 | 0.04 | Why? |
| Anoctamin-1 | 1 | 2017 | 4 | 0.04 | Why? |
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2017 | 10 | 0.04 | Why? |
| Loss of Heterozygosity | 1 | 2017 | 14 | 0.04 | Why? |
| Global Health | 2 | 2018 | 13911 | 0.04 | Why? |
| HLA-DQ beta-Chains | 1 | 2017 | 33 | 0.04 | Why? |
| HLA-DRB1 Chains | 1 | 2019 | 196 | 0.04 | Why? |
| ADP-ribosyl Cyclase 1 | 1 | 2017 | 96 | 0.04 | Why? |
| Proto-Oncogene Proteins c-kit | 1 | 2017 | 59 | 0.04 | Why? |
| Chloride Channels | 1 | 2017 | 51 | 0.04 | Why? |
| Duodenal Diseases | 1 | 2017 | 30 | 0.04 | Why? |
| Germ-Line Mutation | 1 | 2017 | 86 | 0.04 | Why? |
| Sri Lanka | 1 | 2017 | 241 | 0.04 | Why? |
| Oligopeptides | 1 | 2020 | 576 | 0.04 | Why? |
| Induction Chemotherapy | 1 | 2017 | 149 | 0.04 | Why? |
| Clinical Trials, Phase III as Topic | 1 | 2020 | 782 | 0.04 | Why? |
| Cross Infection | 1 | 2018 | 8675 | 0.04 | Why? |
| Carbon | 1 | 2018 | 269 | 0.04 | Why? |
| Antiretroviral Therapy, Highly Active | 1 | 2002 | 952 | 0.04 | Why? |
| Genotyping Techniques | 1 | 2018 | 360 | 0.04 | Why? |
| Medical Overuse | 1 | 2018 | 146 | 0.04 | Why? |
| 3' Untranslated Regions | 1 | 2017 | 318 | 0.04 | Why? |
| Clinical Laboratory Techniques | 2 | 2018 | 23402 | 0.04 | Why? |
| Cost Savings | 1 | 2018 | 296 | 0.04 | Why? |
| MAP Kinase Signaling System | 1 | 2018 | 360 | 0.04 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2017 | 9335 | 0.04 | Why? |
| Leukopenia | 1 | 2017 | 280 | 0.04 | Why? |
| Amino Acid Sequence | 2 | 2017 | 6049 | 0.04 | Why? |
| Chromatography, Affinity | 1 | 2017 | 310 | 0.04 | Why? |
| History, 20th Century | 1 | 2002 | 1282 | 0.04 | Why? |
| Drug Resistance, Viral | 1 | 2002 | 1083 | 0.04 | Why? |
| Necrosis | 1 | 2017 | 532 | 0.04 | Why? |
| Antibody Specificity | 1 | 2019 | 1328 | 0.03 | Why? |
| Professional Practice | 1 | 2018 | 322 | 0.03 | Why? |
| Databases, Nucleic Acid | 1 | 2017 | 272 | 0.03 | Why? |
| Nausea | 1 | 2017 | 457 | 0.03 | Why? |
| Practice Guidelines as Topic | 1 | 2018 | 15421 | 0.03 | Why? |
| Kenya | 1 | 2017 | 887 | 0.03 | Why? |
| Aged, 80 and over | 4 | 2017 | 88759 | 0.03 | Why? |
| Retrospective Studies | 3 | 2021 | 105322 | 0.03 | Why? |
| T-Lymphocytes, Helper-Inducer | 1 | 2017 | 497 | 0.03 | Why? |
| United States Food and Drug Administration | 1 | 2020 | 1276 | 0.03 | Why? |
| Open Reading Frames | 1 | 2020 | 1898 | 0.03 | Why? |
| T-Lymphocytes, Cytotoxic | 1 | 2017 | 552 | 0.03 | Why? |
| Dermatologists | 1 | 2018 | 435 | 0.03 | Why? |
| Sequence Deletion | 1 | 2017 | 674 | 0.03 | Why? |
| Disease-Free Survival | 1 | 2017 | 1654 | 0.03 | Why? |
| Healthy Volunteers | 1 | 2017 | 1444 | 0.03 | Why? |
| Neoplasm Proteins | 1 | 2017 | 501 | 0.03 | Why? |
| Patient Compliance | 1 | 2002 | 1468 | 0.03 | Why? |
| California | 1 | 2018 | 2047 | 0.03 | Why? |
| Amino Acid Substitution | 1 | 2018 | 1706 | 0.03 | Why? |
| Sequence Alignment | 1 | 2017 | 2109 | 0.03 | Why? |
| Gastrointestinal Hemorrhage | 1 | 2017 | 669 | 0.03 | Why? |
| Independent Living | 1 | 2017 | 842 | 0.03 | Why? |
| Autoimmunity | 1 | 2017 | 841 | 0.02 | Why? |
| Neoplasms | 1 | 2018 | 17251 | 0.02 | Why? |
| Immunohistochemistry | 1 | 2017 | 2275 | 0.02 | Why? |
| Communicable Diseases, Emerging | 1 | 2004 | 2523 | 0.02 | Why? |
| Dexamethasone | 1 | 2020 | 2055 | 0.02 | Why? |
| Disease Progression | 2 | 2018 | 13580 | 0.02 | Why? |
| Membrane Glycoproteins | 1 | 2017 | 2273 | 0.02 | Why? |
| Antibodies, Viral | 1 | 2021 | 51949 | 0.02 | Why? |
| Kaplan-Meier Estimate | 1 | 2017 | 4260 | 0.02 | Why? |
| South Africa | 1 | 2018 | 3326 | 0.02 | Why? |
| Proteome | 1 | 2018 | 1812 | 0.02 | Why? |
| Cost of Illness | 1 | 2018 | 1903 | 0.02 | Why? |
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 1573 | 0.02 | Why? |
| Ontario | 2 | 2004 | 1966 | 0.02 | Why? |
| Proteomics | 1 | 2018 | 2481 | 0.02 | Why? |
| Blood Donors | 1 | 2020 | 2956 | 0.02 | Why? |
| Peptide Fragments | 1 | 2017 | 2075 | 0.02 | Why? |
| Gene Expression Regulation | 1 | 2018 | 4020 | 0.02 | Why? |
| ROC Curve | 1 | 2017 | 6024 | 0.02 | Why? |
| Epitopes | 1 | 2017 | 4113 | 0.02 | Why? |
| Surgeons | 1 | 2018 | 2233 | 0.02 | Why? |
| Pyrimidinones | 1 | 2003 | 76 | 0.02 | Why? |
| Survival Rate | 1 | 2018 | 9206 | 0.02 | Why? |
| Sepsis | 1 | 2020 | 3517 | 0.02 | Why? |
| Furans | 1 | 2003 | 156 | 0.02 | Why? |
| Diabetes Mellitus, Type 1 | 1 | 2017 | 1969 | 0.02 | Why? |
| Predictive Value of Tests | 1 | 2017 | 9537 | 0.01 | Why? |
| Pneumonia, Viral | 2 | 2020 | 243684 | 0.01 | Why? |
| United States | 2 | 2020 | 46150 | 0.01 | Why? |
| Coronavirus Infections | 2 | 2020 | 253789 | 0.01 | Why? |
| African Americans | 1 | 2017 | 3363 | 0.01 | Why? |
| Research Design | 1 | 2018 | 5830 | 0.01 | Why? |
| Immunologic Factors | 1 | 2017 | 4206 | 0.01 | Why? |
| Sensitivity and Specificity | 2 | 2017 | 22971 | 0.01 | Why? |
| Immunoassay | 1 | 2017 | 4485 | 0.01 | Why? |
| Salvage Therapy | 1 | 2003 | 417 | 0.01 | Why? |
| Reproducibility of Results | 1 | 2017 | 11304 | 0.01 | Why? |
| Quality of Life | 1 | 2002 | 9820 | 0.01 | Why? |
| Surveys and Questionnaires | 2 | 2018 | 43792 | 0.01 | Why? |
| Length of Stay | 1 | 2018 | 11042 | 0.01 | Why? |
| Disease Models, Animal | 1 | 2018 | 10998 | 0.01 | Why? |
| Severe Acute Respiratory Syndrome | 1 | 2004 | 12361 | 0.01 | Why? |
| Carbamates | 1 | 2003 | 485 | 0.01 | Why? |
| Primary Health Care | 1 | 2018 | 4839 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2018 | 17020 | 0.01 | Why? |
| Betacoronavirus | 2 | 2020 | 204454 | 0.01 | Why? |
| Clinical Trials as Topic | 1 | 2018 | 7330 | 0.01 | Why? |
| Child | 2 | 2018 | 70012 | 0.01 | Why? |
| Antibodies, Monoclonal | 1 | 2017 | 8041 | 0.01 | Why? |
| Genome, Viral | 1 | 2020 | 13157 | 0.01 | Why? |
| Time Factors | 1 | 2021 | 31397 | 0.01 | Why? |
| Mutation | 1 | 2018 | 12376 | 0.01 | Why? |
| Drug Administration Schedule | 1 | 2003 | 2324 | 0.01 | Why? |
| Treatment Outcome | 2 | 2018 | 51732 | 0.01 | Why? |
| Incidence | 1 | 2017 | 25622 | 0.01 | Why? |
| Infant | 1 | 2017 | 30274 | 0.01 | Why? |
| Prospective Studies | 1 | 2018 | 43301 | 0.01 | Why? |
| Emergency Service, Hospital | 1 | 2018 | 14232 | 0.01 | Why? |
| Proportional Hazards Models | 1 | 2003 | 6543 | 0.01 | Why? |
| Survival Analysis | 1 | 2003 | 7592 | 0.01 | Why? |
| Drug Therapy, Combination | 1 | 2003 | 7268 | 0.01 | Why? |
| Diagnosis, Differential | 1 | 2004 | 7220 | 0.01 | Why? |
| Lopinavir | 1 | 2003 | 4308 | 0.01 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 13720 | 0.00 | Why? |
| Viral Load | 1 | 2003 | 15850 | 0.00 | Why? |
| Pandemics | 2 | 2020 | 389249 | 0.00 | Why? |